Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Single-arm, Multicenter Phase 2/3 Clinical Trial Evaluating Avatrombopag in Adult Patients With Aplastic Anemia (AA) Refractory to or Ineligible for Immunosuppressive Therapy or With Relapsed AA After Immunosuppressive Therapy

NCT07786922 is registered in ClinicalTrials.gov with Swedish Orphan Biovitrum as lead sponsor.

NCT NCT07786922
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07786922 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Single-arm, Multicenter Phase 2/3 Clinical Trial Evaluating Avatrombopag in Adult Patients With Aplastic Anemia (AA) Refractory to or Ineligible for Immunosuppressive Therapy or With Relapsed AA After Immunosuppressive Therapy
Lead sponsor
Swedish Orphan Biovitrum
Phase
Phase 2/3
Overall status
Not yet recruiting
Start date
July 31, 2026
Completion date
December 31, 2029
Enrollment
26 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

aplastic anemia